Silverarc Capital Management, LLC 13F holdings
Silverarc Capital Management, LLC reported 65 positions with a total reported value of $898.5M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-13. Top holdings by reported value: ASND ASCENDIS PHARMA A/S (6.1%), CELC CELCUITY INC (5.8%), COGT COGENT BIOSCIENCES INC (5.5%), URGN UROGEN PHARMA LTD (5.3%), IMNM IMMUNOME INC (4.8%). Against 2026-03-31 it opened 19 new positions and exited 21. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Silverarc Capital Management, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 65 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ASND ASCENDIS PHARMA A/S | 206,234 | $55.0M | 6.1% |
| CELC CELCUITY INC | 500,996 | $52.4M | 5.8% |
| COGT COGENT BIOSCIENCES INC | 1,280,707 | $49.6M | 5.5% |
| URGN UROGEN PHARMA LTD | 1,301,979 | $47.9M | 5.3% |
| IMNM IMMUNOME INC | 2,017,009 | $42.7M | 4.8% |
| DNTH DIANTHUS THERAPEUTICS INC | 390,000 | $38.0M | 4.2% |
| RYTM RHYTHM PHARMACEUTICALS INC | 311,461 | $34.6M | 3.8% |
| ORKA ORUKA THERAPEUTICS INC | 352,802 | $33.6M | 3.7% |
| GLUE MONTE ROSA THERAPEUTICS INC | 1,108,295 | $26.8M | 3.0% |
| SNDX SYNDAX PHARMACEUTICALS INC | 1,214,390 | $26.5M | 3.0% |
| ELVN ENLIVEN THERAPEUTICS INC | 489,382 | $24.8M | 2.8% |
| IMVT IMMUNOVANT INC | 619,096 | $23.9M | 2.7% |
| ERAS ERASCA INC | 1,263,026 | $23.1M | 2.6% |
| SGMT SAGIMET BIOSCIENCES INC | 2,927,698 | $22.6M | 2.5% |
| ABVX ABIVAX SA | 169,593 | $22.6M | 2.5% |
| PRAX PRAXIS PRECISION MEDICINES I | 65,679 | $22.0M | 2.4% |
| KOD KODIAK SCIENCES INC | 546,256 | $21.3M | 2.4% |
| DFTX DEFINIUM THERAPEUTICS INC | 400,000 | $18.8M | 2.1% |
| VCYT VERACYTE INC | 318,001 | $18.7M | 2.1% |
| GH GUARDANT HEALTH INC | 99,826 | $15.0M | 1.7% |
| CCCC C4 THERAPEUTICS INC | 3,032,060 | $14.2M | 1.6% |
| ZBIO ZENAS BIOPHARMA INC | 509,789 | $12.9M | 1.4% |
| TRVI TREVI THERAPEUTICS INC | 678,095 | $12.6M | 1.4% |
| HLXC HELIX ACQUISITION CORP III | 1,177,821 | $12.5M | 1.4% |
| ALXO ALX ONCOLOGY HLDGS INC | 5,744,757 | $11.9M | 1.3% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 19 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ELVN ENLIVEN THERAPEUTICS INC | 489,382 | $24.8M | 2.8% |
| SGMT SAGIMET BIOSCIENCES INC | 2,927,698 | $22.6M | 2.5% |
| DFTX DEFINIUM THERAPEUTICS INC | 400,000 | $18.8M | 2.1% |
| ALXO ALX ONCOLOGY HLDGS INC | 5,744,757 | $11.9M | 1.3% |
| MANE VERADERMICS INC | 95,000 | $11.7M | 1.3% |
| AVLN AVALYN PHARMACEUTICALS INC | 330,487 | $10.9M | 1.2% |
| ACRS ACLARIS THERAPEUTICS INC | 1,946,482 | $10.3M | 1.1% |
| AVTX AVALO THERAPEUTICS INC | 500,402 | $9.2M | 1.0% |
| WGS GENEDX HOLDINGS CORP | 122,269 | $8.4M | 0.9% |
| SLDB SOLID BIOSCIENCES INC | 668,450 | $6.7M | 0.7% |
| ARTV ARTIVA BIOTHERAPEUTICS INC | 525,000 | $5.1M | 0.6% |
| QURE UNIQURE NV | 105,000 | $4.8M | 0.5% |
| RACC RESEARCH ALLIANCE CORP III | 360,000 | $3.9M | 0.4% |
| KPTI KARYOPHARM THERAPEUTICS INC | 297,460 | $2.9M | 0.3% |
| RVMD REVOLUTION MEDICINES INC | 10,000 | $1.9M | 0.2% |
| ACHV ACHIEVE LIFE SCIENCE INC | 227,178 | $1.5M | 0.2% |
| CNTB CONNECT BIOPHARMA HLDGS LTD | 545,000 | $1.3M | 0.1% |
| CLRB CELLECTAR BIOSCIENCES INC | 321,728 | $894.4K | <0.1% |
| FHTX FOGHORN THERAPEUTICS INC | 45,975 | $224.4K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 21 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| KALVISTA PHARMACEUTICALS INC | 2,876,407 | $57.9M | 6.8% |
| NUVL NUVALENT INC | 354,914 | $36.4M | 4.3% |
| CENTESSA PHARMACEUTICALS PLC | 466,345 | $18.5M | 2.2% |
| SRRK SCHOLAR ROCK HLDG CORP | 339,613 | $16.7M | 2.0% |
| CGON CG ONCOLOGY INC | 166,349 | $11.3M | 1.3% |
| CLDX CELLDEX THERAPEUTICS INC NEW | 178,378 | $5.7M | 0.7% |
| CYTK CYTOKINETICS INC | 71,203 | $4.7M | 0.6% |
| CLYM CLIMB BIO INC | 684,908 | $4.7M | 0.6% |
| CMPX COMPASS THERAPEUTICS INC | 859,049 | $4.5M | 0.5% |
| SRZN SURROZEN INC | 144,255 | $4.2M | 0.5% |
| ZURA ZURA BIO LTD | 560,651 | $3.3M | 0.4% |
| FULC FULCRUM THERAPEUTICS INC | 419,949 | $3.2M | 0.4% |
| ANNX ANNEXON INC | 496,461 | $2.8M | 0.3% |
| MNPR MONOPAR THERAPEUTICS INC | 43,488 | $2.4M | 0.3% |
| NXTC NEXTCURE INC | 176,057 | $1.9M | 0.2% |
| NMRA NEUMORA THERAPEUTICS INC. | 818,156 | $1.6M | 0.2% |
| EWTX EDGEWISE THERAPEUTICS INC | 42,615 | $1.3M | 0.2% |
| REPL REPLIMUNE GROUP INC | 171,936 | $1.3M | 0.2% |
| GENB GENERATE BIOMEDICINES INC | 100,000 | $1.2M | 0.1% |
| RADX RADIOPHARM THERANOSTICS LTD | 187,406 | $805.8K | <0.1% |
| AARD AARDVARK THERAPEUTICS INC | 33,684 | $127.0K | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ASND ASCENDIS PHARMA A/S | 124,658 | 206,234 | +65.4% | $55.0M |
| ORKA ORUKA THERAPEUTICS INC | 150,908 | 352,802 | +133.8% | $33.6M |
| CELC CELCUITY INC | 357,903 | 500,996 | +40.0% | $52.4M |
| VCYT VERACYTE INC | 179,700 | 318,001 | +77.0% | $18.7M |
| IMVT IMMUNOVANT INC | 414,236 | 619,096 | +49.5% | $23.9M |
| SNDX SYNDAX PHARMACEUTICALS INC | 888,987 | 1,214,390 | +36.6% | $26.5M |
| IBIO IBIO INC | 226,000 | 3,520,490 | +1,457.7% | $6.2M |
| OVID OVID THERAPEUTICS INC | 1,000,000 | 3,101,129 | +210.1% | $8.3M |
| CCCC C4 THERAPEUTICS INC | 1,911,785 | 3,032,060 | +58.6% | $14.2M |
| IMNM IMMUNOME INC | 1,850,278 | 2,017,009 | +9.0% | $42.7M |
| TRVI TREVI THERAPEUTICS INC | 511,127 | 678,095 | +32.7% | $12.6M |
| CMPS COMPASS PATHWAYS PLC | 300,000 | 503,382 | +67.8% | $7.1M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| DNTH DIANTHUS THERAPEUTICS INC | 654,746 | 390,000 | -40.4% | $38.0M |
| GLUE MONTE ROSA THERAPEUTICS INC | 2,002,040 | 1,108,295 | -44.6% | $26.8M |
| ALKS ALKERMES PLC | 460,314 | 113,494 | -75.3% | $5.9M |
| ABVX ABIVAX SA | 302,530 | 169,593 | -43.9% | $22.6M |
| KOD KODIAK SCIENCES INC | 991,930 | 546,256 | -44.9% | $21.3M |
| ZBIO ZENAS BIOPHARMA INC | 1,135,935 | 509,789 | -55.1% | $12.9M |
| SYRE SPYRE THERAPEUTICS INC | 186,618 | 59,959 | -67.9% | $5.3M |
| ERAS ERASCA INC | 1,851,812 | 1,263,026 | -31.8% | $23.1M |
| IRON DISC MEDICINE INC | 196,028 | 82,800 | -57.8% | $6.1M |
| URGN UROGEN PHARMA LTD | 1,503,045 | 1,301,979 | -13.4% | $47.9M |
| ORIC ORIC PHARMACEUTICALS INC | 1,100,010 | 738,873 | -32.8% | $8.0M |
| PRAX PRAXIS PRECISION MEDICINES I | 71,552 | 65,679 | -8.2% | $22.0M |
CIK 1816307 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
